Methods to evaluate the impact of SARS-CoV-2 nucleocapsid mutations on antigen detection by rapid diagnostic testsArticle Published on 2022-09-012022-11-15 Journal: BioTechniques [Category] SARS, 변종, 진단, 치료기술, [키워드] antibodies Antigen antigen detection approach assays BinaxNOW circulating SARS-CoV-2 variants diagnostic tests evaluate evaluate the effect evaluated examined immunoassay immunoblot interfere lateral flow lateral flow assay mutant Mutation nucleocapsid nucleocapsid antigen PanBio produced rapid antigen test Rapid diagnostic test Recombinant protein SARS-CoV-2 SARS-CoV-2 nucleocapsid sensitivity the SARS-CoV-2 variant variants of concern wild-type Wuhan strain [DOI] 10.2144/btn-2022-0020 PMC 바로가기
Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concernNicotiana benthamiana에서 생산된 SARS-CoV-2 변이체의 수용체 결합 도메인 단백질은 우려되는 변이체에 대한 중화 항체를 유도합니다Article Published on 2022-09-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] (alpha Alpha Beta binding domain booster vaccination Booster vaccine cloned COVID-19 cross-reactive Day Delta Delta variants dose Effective vaccines elicit Epsilon evaluated expression vector Fc fragment fragment of Gamma gene encoding health problem human IgG1 immune response immunized immunogenicity induce intramuscularly mutant Mutation Neutralizing antibodies neutralizing antibody Neutralizing antibody response neutralizing antibody responses Nicotiana benthamiana plant-produced recombinant protein produced Protein public health RBD RBD-Fc RBD-Fc fusion protein Receptor-binding domain Recombinant protein required respiratory SARS-CoV-2 SARS-CoV-2 strains SARS-CoV-2 variant SARS-CoV-2 variants Severe acute respiratory syndrome significantly Spread subunit Subunit vaccine tested the receptor-binding domain the vaccine the vaccines transient expression Vaccine variant variant vaccine. variants variants of concern VOCs Wuhan [DOI] 10.1002/jmv.27881 PMC 바로가기 [Article Type] Article
Plasmodium 6-Cysteine Proteins: Functional Diversity, Transmission-Blocking Antibodies and Structural Scaffoldsarticle Published on 2022-07-312024-09-01 Journal: Frontiers in Cellular and Infection Microbiology [Category] 말라리아, [키워드] 6-cysteine proteins malaria monoclonal antibodies Plasmodium Recombinant protein structural biology transmission-blocking [Article Type] article
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trialArticle Published on 2022-07-222022-10-06 Journal: EClinicalMedicine [Category] 진단, [키워드] adverse event adverse events anti-SARS-CoV-2 approach AS03 cellular immunity CEPI clinical study conducted COVID-19 COVID-19 pandemic deviation displaying distribution dose eligible Emergency use enrolled evaluate evaluated flu vaccine foundation geometric mean concentration group groups healthy hospital Humoral immunity IgG antibody immunogenic immunogenicity injection site pain Intervention intramuscularly Investment Local Melinda Gate mitigate myalgia naïve nanoparticle nanoparticle vaccine neutralizing antibody observer-blinded outcome participant per-protocol phase Placebo placebo-controlled primary immunogenicity Protein protocol pseudovirus randomised RBD RBD IgG reached reactogenicity receive recipient Recombinant protein recombinant protein vaccine Registered reported Safety SARS-CoV-2 SARS-COV-2 infection second dose Stage study enrollment Support supported systemic AE systemic AEs T-cell immune responses the receptor-binding domain the vaccine titre Trial vaccination vaccination schedule Vaccine wild-type virus World Health Organization [DOI] 10.1016/j.eclinm.2022.101569 PMC 바로가기 [Article Type] Article
Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings일본 참가자를 대상으로 한 코로나19 백신 임상 1/2상: 중간 결과 보고Clinical Trial Published on 2022-06-152022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Adults Antigen CD4+ T-cell cellular immunity clinical clinical trial comparable convalescent serum COVID-19 COVID-19 vaccine evaluate evaluated healthy IFN-γ IgG IL-2 IL-4 immune reaction immunogenicity initiated interim analysis Intramuscular injection Japanese Mild neutralizing antibody Participants patients peptide phase Placebo placebo-controlled predominant Protein Randomized reactogenicity recombinant Recombinant protein regimen regimens response robust Safe Safety Serious Adverse Event Spike protein the vaccine Trial vaccination Vaccine [DOI] 10.1016/j.vaccine.2022.04.054 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trialBBIBP-CorV로 프라이밍한 후 이종 부스터로서의 NVSI-06-07의 면역원성과 안전성: 2상 시험Clinical Trial Published on 2022-06-062022-09-11 Journal: Signal Transduction and Targeted Therapy [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 Adverse reactions Alpha assigned BBIBP-CorV Beta boost booster booster vaccination conducted control groups coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta double-blinded elicited followed by geometric mean geometric mean titer GMT GMTs group groups healthy Heterologous heterologous prime-boost homologous immunogenic immunogenicity immunogenicity assays inactivated increase Increases indicated individual Mild moderate Neutralizing neutralizing antibody omicron Omicron variant Participants Phase 2 phase 2 trial priming prototype randomised Randomly receive recipient Recombinant protein Safe safety profile SARS-CoV-2 SARS-CoV-2 variant significantly higher systemic adverse reaction three groups vaccination Vaccine variant VOCs [DOI] 10.1038/s41392-022-00984-2 PMC 바로가기 [Article Type] Clinical Trial
Smaller, Stronger, More Stable: Peptide Variants of a SARS-CoV-2 Neutralizing Miniprotein더 작고, 더 강하고, 더 안정적: SARS-CoV-2 중화 미니단백질의 펩타이드 변이체Article Published on 2022-06-042022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] amino acids antiviral activity approach breadth characterized complex de novo Degradation dissect full-length IMPROVE incorporation miniprotein Modification Mutation neutralization Neutralizing neutralizing capacity non-proteinogenic amino acids peptide peptide mimics peptides potency protein expression proteolytic RBD Receptor binding domain Recombinant protein reported resulting retained SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant Smaller Spike protein stability strength structure-based design susceptibility synthetic peptides the RBD the SARS-CoV-2 therapy variant virus virus variant VoC [DOI] 10.3390/ijms23116309 PMC 바로가기 [Article Type] Article
Validation of Serological Methods for COVID-19 and Retrospective Screening of Health Employees and Visitors to the São Paulo University Hospital, BrazilCOVID-19에 대한 혈청학적 방법의 검증 및 브라질 상파울루 대학 병원을 방문하는 의료진 및 방문객에 대한 후향적 검사Article Published on 2022-06-022022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] antigens approach Brazil Clinical studies collected country COVID-19 Critical diagnostic diagnostic test diagnostic tests ECLIA Elecsy Elecsys electrochemiluminescence immunoassay ELISA employee enzyme enzyme-linked immunosorbent assays epidemiological gold gold standard Health health employees house immunoassay in-house ELISA in-house ELISAs infection rates neutralization neutralization test nucleoprotein portion Receptor binding domain Recombinant protein recombinant proteins Roche Diagnostics S1 protein SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 N protein screened Screening screenings sensitivity Sensitivity and specificity serological assays serological test Serological tests serology serum sample serum samples specificity Surveillance the S1 protein the SARS-CoV-2 university university hospital vaccinated individual vaccinated individuals validation virus neutralization test Visitor was used [DOI] 10.3389/fcimb.2022.787411 PMC 바로가기 [Article Type] Article
A Combination of Recombinant HA1-and Nucleoprotein-Based Chitosan Nanoparticles Induces Early and Potent Immune Responses Against the H9N2 Influenza VirusArticle Published on 2022-06-012023-06-22 Journal: Viral immunology [Category] 조류인플루엔자, [키워드] H9N2 influenza virus immune response Nanoparticles Recombinant protein [DOI] 10.1089/vim.2021.0207
Elucidating Design Principles for Engineering Cell-Derived Vesicles to Inhibit SARS-CoV-2 InfectionSARS-CoV-2 감염을 억제하기 위해 세포 유래 소포를 엔지니어링하기 위한 설계 원리 설명Article Published on 2022-05-012022-09-11 Journal: Small (Weinheim an der Bergstrasse, Germany) [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료제, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus addition administration antiviral efficacy binding affinities clinic coronavirus decoy decoys develop drug resistance Engineering evade Extracellular Extracellular vesicles feature foundation Health inhibit inhibitor inhibitors knowledge mAb mAbs monoclonal antibody nanovesicles. neutralization overcome Particle pathogen Pathogens principle provide Quantitative Recombinant protein repeated respiratory SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 virions sera several variant several variants severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 sustained Therapeutics therapy Toxicity Vesicle vesicles Viral viral infections virions [DOI] 10.1002/smll.202200125 PMC 바로가기 [Article Type] Article